• 28. 8. 2017

    The power of synergy - Krka's international symposium in Barcelona

    From the previous century onwards, the medical world has been well aware of the power of synergy, which is achieved by combining medicines; in most cases one medicine is less effective than a fixed-dose combination. This is particularly important when treating chronic diseases, e.g. cardiovascular diseases, which have been the leading cause of mortality and morbidity for decades.

  • 27. 7. 2017

    Krka presented its operating results for the first half of 2017

    The Krka Group sales in the first half of 2017 totalled €655 million, an increase by 8.5% compared to the same period last year, resulting in €91.7 million of net profit. This is a 31% year-on-year increase. The Krka Company sales amounted to €615 million, resulting in €83.6 million of net profit.

  • 7. 7. 2017

    Krka Group operations in the first half of 2017

    The Krka Company Supervisory Board was convened today and briefed by the Management Board on preliminary operations results for the first half of 2017 and on the acquisition project in China. The Supervisory Board will review the final results for the first half of 2017 at its meeting on 26 July 2017, and Krka’s performance results will be published on the subsequent day. The 23rd Annual General Meeting of the Krka Company was also held today, starting at 1 p. m. at the Šport Hotel in Otočec, Slovenia. Krka’s President of the Management Board presented to the shareholders all the information previously disclosed to the members of the Supervisory Board.

  • 29. 5. 2017

    Krka Awards Day

    At a ceremony near the Otočec castle we conferred recognition awards to those employees who celebrated their many years of service, best employees and best managers as well as those who proposed the most useful proposals and improvements.

  • 22. 5. 2017

    Choice for Krka's medicine is choice for a clinically proven medicine

    Extensive clinical experience is one of the key added values of Krka's medicines. It demonstrates that treatment with Krka’s medicines is supported by clinical evidence.